AC Immune SA (NASDAQ: ACIU) hosted Dr. Oscar Hansson, a top research scientist, on a webinar about a-synuclein. This is a therapeutic target to treat neurodegenerative diseases. Dr. Hansson also presented data indicating that ACI-12589, a radiotracer that the company developed, was the first to differentiate between multiple system atrophy and other neurodegenerative diseases such as Parkinson’s disease. It could also distinguish healthy patients.
Dr. Hansson recruited about 200 volunteers for his presentation. A video of the webinar is up on the company’s website.
The radiotracer can differentiate various neurological illnesses
According to Dr. Hansson, the company has researched radiotracers for many years. For this reason, AC Immune is excited to have found the only radiotracer capable of detecting multiple system atrophy in people.
Dr. Hansson adds that the new development could open the door for other parties to develop groundbreaking tracers for Lewy Body Dementia and Parkinson’s disease through ACI-12589. The doctor and his team will conduct further studies on the topic.
AC Immune’s CEO, Professor Andrea Pfeifer, adds that its scientists will continue their research in neurodegenerative diseases with its Morphomer discover platform and partners.
Professor Pfeifer adds that the development of ACI-12589 for multiple system atrophy opens up new paths for translational medicine, such as a regulatory mechanism to develop biomarkers for NeuroOrphan.
The solutions could make clinical trials more effective
Moreover, distinguishing between multiple system atrophy and other neurodegenerative diseases will ensure more effective clinical trials. The reason is that researchers could choose better patients by screening them for the disease. They could also monitor the impact of therapies more efficiently.
Furthermore, this new development will allow the company to create more effective medications for neurodegenerative disorders by developing drugs that target specific locations. It would also enable AC Immune to make vaccines or therapies that prevent or slow down disease progression.
Other than ACI-12589, the company is working on other projects. For example, AC Immune is trying to develop therapies for Parkinson’s disease and Alzheimer’s. The company is in the midst of several clinical trials, which it will report soon.
AC Immune is a company that focuses on developing treatments for neurodegenerative disorders. The company uses Morphomer and SupraAntigen, two technology platforms, to develop its portfolio of therapies.
